At SCYNEXIS, we are bringing a ground-breaking class of drugs to the battle by developing innovative products that have the strength, safety, and versatility to defeat even the most insidious fungal diseases. We are committed to positively impacting the lives of patients suffering from fungal infections — from the most common to the difficult-to-treat and deadliest. (NASDAQ: SCYX) The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization.